Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC “teaser” sites

This article was originally published in The Tan Sheet

Executive Summary

Commission's three mock Web sites - "Arthriticure," "Virility Plus" and "Nordicalite" - received over 20,000 hits in last two years, Chairman Timothy Muris tells House Energy & Commerce subcommittee hearing Nov. 7. Sites tout bogus products and warn consumers of real-life scams. Dietary supplements "will continue to receive special attention" from FTC, Muris vows. "False or deceptive claims in the advertising for these products are especially rampant," he asserts, pointing to ever-increasing supplement sales and advent of the Internet as a marketing tool. FTC recently announced enforcement efforts targeting colloidal silver supplements, other fraudulent anthrax cures (1"The Tan Sheet" Nov. 5, p. 3)...

You may also be interested in...

FDA, FTC, 30 State AGs Join Forces To Combat Fraudulent Anthrax Products

The Federal Trade Commission is renewing efforts to track down colloidal silver supplements sold online under a federal and state multi-agency campaign against fraudulent products indicated for anthrax

Bharat Biotech Plans Coronavirus Vaccine

After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.

HLB Takes First Expansion Step Via Immunomic Acquisition

South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts